ArticleObesity facts2026
Longitudinal Changes in Body Composition, Adaptive Thermogenesis, and Muscle Strength in Patients with Obesity Treated with Semaglutide.
Article in Obesity facts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity management increasingly emphasizes not only total weight reduction but also the quality of weight loss, reflecting the balance between fat and lean tissue changes, preservation of strength capacity, and changes in energy expenditure. Semaglutide is effective for weight management, yet its integrated real-world effects on body composition, resting energy expenditure (REE), adaptive thermogenesis (AT), and muscle strength in adults with obesity without diabetes remain incompletely characterized.
methodsWe performed a single-center, retrospective observational study in routine care at the Obesity Treatment Unit (UTIO), Hospital Universitari Vall d'Hebron (Barcelona, Spain), January 2024-December 2025. Adults (≥18 years) with obesity (BMI ≥ 30 kg/m2) and without diabetes were included if baseline (V1) and 12-month (V2) data were available. Patients were classified as lifestyle educational program (n = 39) or lifestyle educational program plus semaglutide (n = 44), requiring ≥70% exposure during follow-up. Anthropometry, dominant handgrip strength, body composition by bioelectrical impedance analysis, and REE by indirect calorimetry were assessed at V1 and V2. Musculoskeletal remodeling was evaluated using continuous, age-, and BMI-dependent Skeletal Muscle Index Standardized Deviation Scores (SMI-SDS) validated against gold-standard MRI data. Between-group differences were tested using ANCOVA or rank ANCOVA with the absolute change from baseline (delta [Δ]) as the dependent variable, adjusted for the baseline age, gender, and body weight; partial eta squared (η2p) was reported. A study-specific predictive equation was derived to estimate REE and calculate AT from measured versus predicted REE at baseline and 12 months, with an external sensitivity analysis using the Ostendorf equation.
resultsSemaglutide group was associated with significantly greater 12-month reductions in body weight (Δ -11.0 kg, p = 0.001), BMI (Δ -4.0 kg/m2, p = 0.001), and waist circumference (Δ -7.0 cm, p = 0.002) versus lifestyle group. WtHR showed a small, nonsignificant increase with lifestyle group (Δ + 0.01) versus a significant decrease in semaglutide group (Δ -0.04); the between-group difference was statistically significant after covariate adjustment (p < 0.001). Bioelectrical impedance analysis showed significant reductions in adiposity (including fat mass and indicative visceral fat area trends) in semaglutide group; skeletal muscle mass (SMM) and fat-free mass (FFM) also decreased in the semaglutide group (SMM = 29.9 to 28.7 kg; FFM = 53.8 to 52.7 kg; p < 0.001). Crucially, reference-based muscle evaluation revealed a highly significant structural improvement in SMI-SDS selectively in semaglutide group (delta 0.52 vs. 0.09 in lifestyle group; adjusted p < 0.001), demonstrating qualitative muscle mass optimization despite absolute lean tissue loss. Absolute handgrip strength was preserved in both groups, while relative handgrip strength improved with semaglutide (adjusted p = 0.003; η2p = 0.110). REE decreased in both groups; the adjusted analyses identified a p value at the limit of statistical significance (adjusted p = 0.050; η2p = 0.049). The AT analysis showed that part of this decline exceeded what would be expected from changes in FM, FFM, age, and gender. However, the magnitude of AT did not differ significantly between semaglutide group (delta AT: -210.2 kcal/day) and lifestyle group (delta AT: -373.4 kcal/day). RQ showed no differences between groups in terms of preference for fat oxidation.
conclusionIn routine obesity care, semaglutide was associated with reductions in total adiposity and improvements in central anthropometric markers. Absolute handgrip strength was preserved in both groups. Crucially, reference-based muscle evaluation revealed a highly significant structural improvement in SMI-SDS selectively in semaglutide group. AT in both groups showed a decline in REE beyond that expected from FFM, FM, age, and gender, with no significant between-group differences. Comprehensive monitoring with body composition, handgrip strength, and indirect calorimetry may enhance follow-up of patients receiving obesity management medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.